Effect of the combination of pegylated liposomal doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed/refractory multiple myeloma compared with bortezomib alone

被引：0
|
作者：
Harousseau, J. L.
Nagler, A.
Sonneveld, P.
Blade, J.
Hajek, R.
Spencer, A.
Robak, T.
Xiu, L.
Zhuang, S. H.
Orlowski, R. Z.
机构：
[1] Hoteldieu Hosp, Nantes, France
[2] Chaim Sheba Med Ctr, Tel Hashomer, Israel
[3] Erasmus MC, Rotterdam, Netherlands
[4] Hosp Clin I Prov, Barcelona, Spain
[5] Interni Hematoonkol Klin Fak Brno, Brno, Czech Republic
[6] Alfred Hosp, Melbourne, Vic, Australia
[7] Med Univ Lodz, Lodz, Poland
[8] Johnson & Johnson PRD, Raritan, NJ USA
[9] Univ N Carolina, Chapel Hill, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8002
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Weekly Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone Is a Safe and Effective Therapy for Elderly Patients With Relapsed/Refractory Multiple Myeloma
    Gozzetti, Alessandro
    Fabbri, Alberto
    Oliva, Stefania
    Marchini, Elena
    Bocchia, Monica
    Defina, Marzia
    Lauria, Francesco
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (01): : 68 - 72
  • [22] PROGNOSTICATION OF RESPONSE TO BORTEZOMIB, PROGRESSION FREE AND OVERALL SURVIVAL IN RELAPSED/REFRACTORY MYELOMA PATIENTS
    Kyrtsonis, M. C.
    Vassilakopoulos, T. P.
    Sachanas, S.
    Panagoulias, G.
    Bartzis, V.
    Anargyrou, K.
    Dimou, M.
    Tzenou, T.
    Masouridis, S.
    Kalpadakis, C.
    Dimitrakopoulou, E.
    Kokoris, S. I.
    Dimitriadou, E.
    Siakantaris, M. P.
    Angelopoulou, M. K.
    Panayiotidis, P.
    Pangalis, G. A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 263 - 263
  • [23] Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma
    Voorhees, Peter M.
    Gasparetto, Cristina
    Moore, Dominic T.
    Winans, Diane
    Orlowski, Robert Z.
    Hurd, David D.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (07): : 424 - 432
  • [24] The effect of pegylated liposomal doxorubicin plus bortezomib in multiple myeloma patients with renal insufficiency
    Blade, J.
    Sonneveld, P.
    San Miguel, J.
    Sutherland, H.
    Hajek, R.
    Nagler, A.
    Spencer, A.
    Robak, T.
    Harousseau, J. L.
    Orlowski, R. Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma
    Waterman, Gabriel N.
    Yellin, Ori
    Swift, Regina A.
    Mapes, Russell
    Eades, Benjamin
    Ackerman, Emily
    Berenson, James R.
    ANNALS OF HEMATOLOGY, 2011, 90 (02) : 193 - 200
  • [26] A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma
    Gabriel N. Waterman
    Ori Yellin
    Regina A. Swift
    Russell Mapes
    Benjamin Eades
    Emily Ackerman
    James R. Berenson
    Annals of Hematology, 2011, 90 : 193 - 200
  • [27] Relapsed or Refractory Multiple Myeloma: Prospective Study with Bortezomib, Non-Pegylated Liposomal Doxorubicin and Dexamethason (PAD Regimen)
    Falcone, Antonietta Pia
    Sanpaolo, Grazia
    Rossi, Giovanni
    Bodenizza, Carlo
    Carella, Angelo Michele
    Dell' Olio, Matte
    Greco, Michele Mario
    La Sala, Antonio
    Mantuano, Saverio
    Melillo, Lorella
    Merla, Emanuela
    Nobile, Michele
    Scalzulli, Potito R.
    Capalbo, Silvana
    Cascavilla, Nicola
    BLOOD, 2012, 120 (21)
  • [28] Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients
    Buda, Gabriele
    Orciuolo, Enrico
    Galimberti, Sara
    Pelosini, Matteo
    Petrini, Mario
    ANNALS OF HEMATOLOGY, 2011, 90 (09) : 1115 - 1116
  • [29] Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients
    Gabriele Buda
    Enrico Orciuolo
    Sara Galimberti
    Matteo Pelosini
    Mario Petrini
    Annals of Hematology, 2011, 90 : 1115 - 1116
  • [30] Phase I/II study of bortezomib in combination with liposomal doxorubicin and melphalan in relapsed or refractory multiple myeloma.
    Chari, A
    Kaplan, L
    Linker, C
    Damon, LE
    Navarro, WH
    Martin, T
    BLOOD, 2005, 106 (11) : 379B - 379B
12345